scholarly journals Typically asymptomatic but with robust antibody formation: Childrens unique humoral immune response to SARS-CoV-2

2021 ◽  
Author(s):  
Hanna Renk ◽  
Alex Dulovic ◽  
Matthias Becker ◽  
Dorit Fabricius ◽  
Maria Zernickel ◽  
...  
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Age Groups ◽  
Asymptomatic Infection ◽  
Serological Response ◽  
Vaccination Programs ◽  
Humoral Immune ◽  
Viral Spread ◽  
Antibody Assays

Background: Long-term persistence of antibodies against SARS-CoV-2, particularly the SARS-CoV-2 Spike Trimer, determines individual protection against infection and potentially viral spread. The quality of children's natural humoral immune response following SARS-CoV-2 infection is yet incompletely understood but crucial to guide pediatric SARS-CoV-2 vaccination programs. Methods: In this prospective observational multi-center cohort study, we followed 328 households, consisting of 548 children and 717 adults, with at least one member with a previous laboratory-confirmed SARS-CoV-2 infection. The serological response was assessed at 3-4 months and 11-12 months after infection using a bead-based multiplex immunoassay for 23 human coronavirus antigens including SARS-CoV-2 and its Variants of Concern (VOC) and endemic human coronaviruses (HCoVs), and additionally by three commercial SARS-CoV-2 antibody assays. Results: Overall, 33.76% of SARS-CoV-2 exposed children and 57.88% adults were seropositive. Children were five times more likely to have seroconverted without symptoms compared to adults. Despite the frequently asymptomatic course of infection, children had higher specific antibody levels, and their antibodies persisted longer than in adults (96.22% versus 82.89% still seropositive 11-12 months post infection). Of note, symptomatic and asymptomatic infections induced similar humoral responses in all age groups. In symptomatic children, only dysgeusia was found as diagnostic indicator of COVID-19. SARS-CoV-2 infections occurred independent of HCoV serostatus. Antibody binding responses to VOCs were similar in children and adults, with reduced binding for the Beta variant in both groups. Conclusions: The long-term humoral immune response to SARS-CoV-2 infection in children is robust and may provide long-term protection even after asymptomatic infection. (Study ID at German Clinical Trials Register: 00021521)

scholarly journals Robust and durable serological response following pediatric SARS-CoV-2 infection

2022 ◽  
Vol 13 (1) ◽  
Author(s):  
Hanna Renk ◽  
Alex Dulovic ◽  
Alina Seidel ◽  
Matthias Becker ◽  
Dorit Fabricius ◽  
...  
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Age Groups ◽  
Asymptomatic Infection ◽  
Pseudotyped Virus ◽  
Serological Response ◽  
Vaccination Programs ◽  
Humoral Immune ◽  
Antibody Assays ◽  
Human Coronaviruses

AbstractThe quality and persistence of children’s humoral immune response following SARS-CoV-2 infection remains largely unknown but will be crucial to guide pediatric SARS-CoV-2 vaccination programs. Here, we examine 548 children and 717 adults within 328 households with at least one member with a previous laboratory-confirmed SARS-CoV-2 infection. We assess serological response at 3–4 months and 11–12 months after infection using a bead-based multiplex immunoassay for 23 human coronavirus antigens including SARS-CoV-2 and its Variants of Concern (VOC) and endemic human coronaviruses (HCoVs), and additionally by three commercial SARS-CoV-2 antibody assays. Neutralization against wild type SARS-CoV-2 and the Delta VOC are analysed in a pseudotyped virus assay. Children, compared to adults, are five times more likely to be asymptomatic, and have higher specific antibody levels which persist longer (96.2% versus 82.9% still seropositive 11–12 months post infection). Of note, symptomatic and asymptomatic infections induce similar humoral responses in all age groups. SARS-CoV-2 infection occurs independent of HCoV serostatus. Neutralization responses of children and adults are similar, although neutralization is reduced for both against the Delta VOC. Overall, the long-term humoral immune response to SARS-CoV-2 infection in children is of longer duration than in adults even after asymptomatic infection.

scholarly journals Long-Term Humoral Immune Response in Persons with Asymptomatic or Mild SARS-CoV-2 Infection, Vietnam

2021 ◽  
Vol 27 (2) ◽  
pp. 663-666
Author(s):  
Huynh Kim Mai ◽  
Nguyen Bao Trieu ◽  
Trinh Hoang Long ◽  
Hoang Tien Thanh ◽  
Nguyen Dinh Luong ◽  
...  
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Humoral Immune

Long-Term Oral Administration of Ginseng Extract Modulates Humoral Immune Response and Spleen Cell Functions

2005 ◽  
Vol 33 (04) ◽  
pp. 651-661 ◽  
Author(s):  
Chian-Jiun Liou ◽  
Wen-Chung Huang ◽  
Jerming Tseng
Keyword(s):  
Immune Response ◽  
Oral Administration ◽  
Spleen Cell ◽  
Humoral Immune Response ◽  
Ginseng Root ◽  
Spleen Cells ◽  
Ginseng Extract ◽  
Humoral Immune ◽  
Cell Functions

Ginseng radix (Panax ginseng C.A. Meyer) is a popular herbal medicine in Oriental countries. We investigated the effect of long-term oral administration of ginseng extract on the antigen-specific antibody response. Male BALB/c mice were treated orally for 30 consecutive days with 2 g/kg of a 50% ethanol extract of ginseng root. Mice treated with ginseng and immunized with ovalbumin (OVA), resulting in an eight-fold increase in titers of anti-OVA immunoglobulin (Ig)G in the serum compared to the group receiving OVA immunization without ginseng treatment; the level of IgG was also significantly elevated in the mice treated with ginseng and immunized with OVA. Mice treated with ginseng without OVA immunization exhibited significantly reduced IgG and IgA production by spleen cells. However, IgG production was not affected in mice treated with ginseng and OVA immunization in spleen cells. Interleukin (IL)-2, interferon (IFN)-γ and IL-4 secretion by spleen cells from either ginseng-treated mice or OVA-immunized mice were down-regulated compared to that in the control group; while the production of IL-10 was unchanged. The percentage of CD8+ cells was significantly reduced in spleen cells from ginseng-treated, OVA-immunized mice. Thus, long-term oral administration of ginseng extract appears to potentiate humoral immune response but suppress spleen cell functions.

scholarly journals Reduced schedule of human anti rabies immunization with Fuenzalida & Palacios vaccine

1989 ◽  
Vol 31 (1) ◽  
pp. 23-27 ◽  
Author(s):  
Carlos Roberto Zanetti ◽  
Silvana Regina Favoretto ◽  
Milene Silva Tino ◽  
Avelino Albas ◽  
Elizabeth Juliana G. Valentini ◽  
...  
Keyword(s):  
Immune Response ◽  
Immune Responses ◽  
Humoral Immune Response ◽  
The Other ◽  
Double Dose ◽  
Humoral Immune ◽  
Cellular Immune Responses ◽  
Lymphoblastic Transformation ◽  
Cellular Immune

The present study evaluates the humoral and cellular immune responses in 35 volunteers submited to short antirabies vaccination schedules with the Fuenzalida & Palacios vaccine based on the administration of doses on non consecutive days. The volunteers were divided into two groups. The first group received a total number of five doses given on days 0, 4, 7, 20 and 35. The other group received four doses, the first one being a double dose given on day 0 and than three other single doses on days 7, 20 and 35. The evaluation of humoral immune response was carried out by serum neutralization (SN) and indirect immunofluorescense (IIF) tests, while the cellular immune response was evaluated by lymphoblastic transformation assay (LTA) and skin test (ST). According to our results these reduced schedules elicited early and effective humoral and cellulafimmune responses to rabies antigen suggesting that new reduced schedules should be extensively studied in order to give the proper bases to the proposition of changes in the current long-term schedule.

scholarly journals Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation

2019 ◽  
Vol 93 (18) ◽  
Author(s):  
Chloé Pasin ◽  
Irene Balelli ◽  
Thierry Van Effelterre ◽  
Viki Bockstal ◽  
Laura Solforosi ◽  
...  
Keyword(s):  
Immune Response ◽  
Antibody Response ◽  
Humoral Immune Response ◽  
Phase 1 ◽  
Humoral Response ◽  
Enzyme Linked Immunosorbent Assay ◽  
Phase 1 Trials ◽  
Humoral Immune ◽  
Boost Immunization

ABSTRACT The Ebola vaccine based on Ad26.ZEBOV/MVA-BN-Filo prime-boost regimens is being evaluated in multiple clinical trials. The long-term immune response to the vaccine is unknown, including factors associated with the response and variability around the response. We analyzed data from three phase 1 trials performed by the EBOVAC1 Consortium in four countries: the United Kingdom, Kenya, Tanzania, and Uganda. Participants were randomized into four groups based on the interval between prime and boost immunizations (28 or 56 days) and the sequence in which Ad26.ZEBOV and MVA-BN-Filo were administered. Consecutive enzyme-linked immunosorbent assay (ELISA) measurements of the IgG binding antibody concentrations against the Kikwit glycoprotein (GP) were available for 177 participants to assess the humoral immune response up to 1 year postprime. Using a mathematical model for the dynamics of the humoral response, from 7 days after the boost immunization up to 1 year after the prime immunization, we estimated the durability of the antibody response and the influence of different factors on the dynamics of the humoral response. Ordinary differential equations (ODEs) described the dynamics of antibody response and two populations of antibody-secreting cells (ASCs), short-lived (SL) and long-lived (LL). Parameters of the ODEs were estimated using a population approach. We estimated that half of the LL ASCs could persist for at least 5 years. The vaccine regimen significantly affected the SL ASCs and the antibody peak but not the long-term response. The LL ASC compartment dynamics differed significantly by geographic regions analyzed, with a higher long-term antibody persistence in European subjects. These differences could not be explained by the observed differences in cellular immune response. IMPORTANCE With no available licensed vaccines or therapies, the West African Ebola virus disease epidemic of 2014 to 2016 caused 11,310 deaths. Following this outbreak, the development of vaccines has been accelerated. Combining different vector-based vaccines as heterologous regimens could induce a durable immune response, assessed through antibody concentrations. Based on data from phase 1 trials in East Africa and Europe, the dynamics of the humoral immune response from 7 days after the boost immunization onwards were modeled to estimate the durability of the response and understand its variability. Antibody production is maintained by a population of long-lived cells. Estimation suggests that half of these cells can persist for at least 5 years in humans. Differences in prime-boost vaccine regimens affect only the short-term immune response. Geographical differences in long-lived cell dynamics were inferred, with higher long-term antibody concentrations induced in European participants.

scholarly journals Humoral immune response and delayed-type hypersensitivity in rabbits infected with Trypanosoma equiperdum

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Tiziana Di Febo ◽  
Ivanka Krasteva ◽  
Barbara Bonfini ◽  
Manuela Tittarelli ◽  
Osvaldo Matteucci ◽  
...  
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Skin Tests ◽  
Delayed Type Hypersensitivity ◽  
Serological Response ◽  
Protein Extract ◽  
Serological Tests ◽  
Humoral Immune ◽  
Trypanosoma Equiperdum

Abstract Trypanosoma equiperdum is the causative agent of dourine, a parasitic venereal disease of equids. In this work, rabbits were infected with T. equiperdum strain OVI; serological tests (complement fixation test, ELISA and immunoblotting), used for the diagnosis of dourine in horses, were applied to study rabbit humoral immune response and to characterise T. equiperdum antigen pattern recognised by antibodies from infected rabbits. Moreover a protein extract of T. equiperdum strain OVI was produced and tested in skin tests on infected rabbits to detect the cell-mediated response induced by T. equiperdum, in order to evaluate its use in the field diagnosis of dourine. Sera of infected rabbits recognized in immunoblotting Trypanosoma protein bands with molecular weight below 37 kDa, providing a serological response comparable with that already observed in dourine infected horses. Moreover the trypanosome protein extract was capable to produce in vivo delayed-type hypersensitivity (DHT Type IV) in rabbits and proved itself to be non-toxic and non-sensitizing.

scholarly journals Nasal and Salivary Mucosal Humoral Immune Response Elicited by mRNA BNT162b2 COVID-19 Vaccine Compared to SARS-CoV-2 Natural Infection

Vaccines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1499
Author(s):  
Mariapia Guerrieri ◽  
Beatrice Francavilla ◽  
Denise Fiorelli ◽  
Marzia Nuccetelli ◽  
Francesco Maria Passali ◽  
...  
Keyword(s):  
New York ◽  
Immune Response ◽  
Immune Responses ◽  
Humoral Immune Response ◽  
Natural Infection ◽  
Serum Antibody ◽  
Vaccine Dose ◽  
Humoral Immune ◽  
Antibody Assays ◽  
Nasal Secretions

SARS-CoV-2 antibody assays are crucial in managing the COVID-19 pandemic. Approved mRNA COVID-19 vaccines are well known to induce a serum antibody responses against the spike protein and its RBD. Mucosal immunity plays a major role in the fight against COVID-19 directly at the site of virus entry; however, vaccine abilities to elicit mucosal immune responses have not been reported. We detected anti-SARS-CoV-2 IgA-S1 and IgG-RBD in three study populations (healthy controls, vaccinated subjects, and subjects recovered from COVID-19 infection) on serum, saliva, and nasal secretions using two commercial immunoassays (ELISA for IgA-S1 and chemiluminescent assay for IgG-RBD). Our results show that the mRNA BNT162b2 vaccine Comirnaty (Pfizer/BioNTech, New York, NY, USA) determines the production of nasal and salivary IgA-S1 and IgG-RBD against SARS-CoV-2. This mucosal humoral immune response is stronger after the injection of the second vaccine dose compared to subjects recovered from COVID-19. Since there is a lack of validated assays on saliva and nasal secretions, this study shows that our pre-analytical and analytical procedures are consistent with the data. Our findings indicate that the mRNA COVID-19 vaccine elicits antigen-specific nasal and salivary immune responses, and that mucosal antibody assays could be used as candidates for non-invasive monitoring of vaccine-induced protection against viral infection.

Sign in / Sign up

Export Citation Format

Share Document